| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| შპს ელკადენტ | Medical Devices | 36.3% | 97th pct | 35 |
| შპს პანაცეა | Pharma | 4.6% | 20th pct | 103 |
| შპს კინველ ჯორჯია | FMCG | -0.1% | 19th pct | 532 |
| შპს ფიფ კო. ლტდ | Pharma | 0.9% | 17th pct | 103 |
| სს ჰუმანითი ჯორჯია | Pharma | — | no FY data | 103 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | შპს პანაცეა | შპს ფიფ კო. ლტდ | შპს კინველ ჯორჯია | შპს ელკადენტ | სს ჰუმანითი ჯორჯია |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 41.0% | 28.0% | 11.5% | 36.6% | — |
| EBITDA Margin | 4.6% | 0.9% | -0.1% | 36.3% | — |
| EBITDAR | 198 | 52 | -5 | 1,298 | — |
| EBITDAR Margin | 5.5% | 1.4% | -0.1% | 36.3% | — |
| EBIT Margin | 1.8% | 0.8% | -0.3% | 36.3% | — |
| Net Profit Margin | 5.0% | -0.4% | -0.3% | 32.1% | — |
| Operating Expense % of Sales | 36.4% | 27.1% | 11.6% | 0.3% | — |
| Returns | |||||
| Return on Assets (ROA) | 5.6% | -0.4% | -0.8% | 33.9% | — |
| Return on Equity (ROE) | 6.7% | N/A | -1.3% | 34.1% | — |
| ROIC [EBIT / Invested Capital] | 2.3% | 0.9% | -1.4% | 62.1% | — |
| Leverage & liquidity | |||||
| Debt-to-Assets | 7.9% | 104.8% | 0.0% | 0.0% | — |
| Debt-to-Equity | 0.09x | -20.44x | 0.00x | 0.00x | — |
| Debt-to-EBITDA | 1.53x | 107.19x | N/A | 0.00x | — |
| Equity-to-Assets | 82.8% | -5.1% | 60.0% | 99.6% | — |
| Net Debt | 243 | 3,362 | -30 | -1,272 | — |
| Cash & Equivalents | 9 | 37 | 30 | 1,272 | — |
| Total Debt | 252 | 3,399 | N/A | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 3.92x | N/A | 2.28x | 213.93x | — |
| Quick Ratio | 3.92x | N/A | 2.28x | 213.93x | — |
| Cash Ratio | 0.02x | N/A | 0.06x | 84.68x | — |
| Total Current Assets | 2,171 | 3,217 | 1,169 | 3,214 | — |
| Total Current Liabilities | 553 | N/A | 513 | 15 | — |
| Inventory | N/A | N/A | N/A | N/A | — |
| Trade Receivables | 983 | 1,261 | 131 | 678 | — |
| Trade Payables | 301 | N/A | 513 | 15 | — |
| Net Working Capital | 1,617 | 3,217 | 656 | 3,199 | — |
| Net Working Capital % of Revenue | 44.7% | 89.0% | 18.2% | 89.4% | — |
| Trade Working Capital | 681 | 1,261 | -382 | 663 | — |
| Trade Working Capital % of Revenue | 18.9% | 34.9% | -10.6% | 18.5% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | — |
| Receivables Turnover | 3.68x | 2.87x | 27.42x | 5.28x | — |
| Days Sales Outstanding (DSO) | 99.2 | 127.3 | 13.3 | 69.2 | — |
| Payables Turnover | 7.08x | N/A | 6.21x | 150.87x | — |
| Days Payable Outstanding (DPO) | 51.5 | N/A | 58.8 | 2.4 | — |
| Cash Conversion Cycle | 47.7 days | 127.3 days | -45.4 days | 66.7 days | — |
| Asset Turnover | 1.13x | 1.11x | 2.78x | 1.06x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | N/A | 130 | 5,945 | — |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | 117 | 5,943 | — |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | 457.8% | — |
| Dividends Declared | N/A | N/A | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | — |